# US 2025/0164507 A1 · Compositions and methods for diagnosing and treating cardiomyopathy in a feline

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0164507 A1
- Document ID: US20250164507A1
- Status: Published application
- Kind: A1
- Application number: 18/896,071
- Filed: 2024-09-25
- Published: 2025-05-22
- Earliest claimed: 2023-11-17
- Assignees: Societe des Produits Nestle S.A.
- Applicants: Société des Produits Nestlé S.A.
- Inventors: Qinghong LI
- Web page: https://patentgrep.com/patent/US20250164507A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A23K 50/40: for carnivorous animals, e.g. cats or dogs
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- G01N 2333/575: Hormones
- G01N 2800/325: Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A23K: FODDER
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods and compositions for diagnosing and enabling treatment of cardiomyopathy (CM) in a feline. In one embodiment, a method of diagnosing CM in a feline can comprise measuring an amount of at least one metabolite from the feline; comparing the amount of the at least one metabolite from the feline to a corresponding predetermined value or a corresponding predetermined range; and diagnosing the feline as preclinical CM, clinical CM, or not having CM, based on the comparison.

## Claims

### Claim 1

A method of diagnosing cardiomyopathy (CM) in a feline, the method comprising: measuring an amount of at least one metabolite from the feline, wherein the at least one metabolite is selected from the group consisting of tauro-beta-muricholate, 1-stearoyl-2-linoleoyl-GPE (18:0/18:2), 1-stearoyl-2-oleoyl-GPE (18: 0/18:1), 1-stearoyl-2-linoleoyl-GPI (18:0/18:2), 1-behenoyl-GPC (22:0), 1-linoleoyl-GPI (18:2), taurodeoxycholic acid 3-sulfate, 1-palmitoyl-2-linoleoyl-GPE (16:0/18:2), asparagine, 1-palmitoyl-2-oleoyl-GPE (16:0/18:1), 1-arachidoyl-GPC (20:0), phosphatidylcholine (18:0/20:2, 20:0/18:2), taurodeoxycholate, glycerol, cystine, C-glycosyltryptophan, cysteine-glutathione disulfide, N-acetylglucosaminylasparagine, N-lactoyl valine, 5-(galactosylhydroxy)-lysine, 3-hydroxymyristate, hydroxyasparagine, guanidinosuccinate, N-lactoyl tyrosine, 1-methylhistidine, glucuronate, ribonate, 1-methylguanidine, N,N-dimethylalanine, 11-dehydrocorticosterone, cortisol, 2R,3R-dihydroxybutyrate, mannitol/sorbitol, n-propanol glucuronide, and mixtures thereof;
comparing the amount of the at least one metabolite from the feline to a corresponding predetermined value or a corresponding predetermined range; and
diagnosing the feline as preclinical CM, clinical CM, or not having CM, based on the comparison.

### Claim 2 (depends on 1)

The method of claim 1, comprising obtaining a sample of at least one of serum or plasma from the feline, wherein the measuring of the amount of each of the at least one metabolite is performed on the sample of at least one of serum or plasma.

### Claim 3 (depends on 1)

The method of claim 1, wherein the corresponding predetermined value or the corresponding predetermined range is from Table 1:
TABLE 1
Diagnostic Range
(measured as normalized
relative abundance)
Chemical
Healthy
Preclinical
Clinical
tauro-beta-muricholate
>−0.682
[−1.689, −0.682]
<−1.689
1-stearoyl-2-linoleoyl-GPE (18:0/18:2)
>0.042
[−0.6927, 0.042]
<−0.6927
1-stearoyl-2-oleoyl-GPE (18:0/18:1)
>0.046
[−0.8282, 0.046]
<−0.8282
1-stearoyl-2-linoleoyl-GPI (18:0/18:2)
>−0.009
[−0.2701, −0.009]
<−0.2701
1-behenoyl-GPC (22:0)
>0.053
[−0.0355, 0.053]
<−0.0355
1-linoleoyl-GPI (18:2)
>0.147
[−0.0834, 0.147]
<−0.0834
taurodeoxycholic acid 3-sulfate
>−0.578
[−1.2202, −0.578]
<−1.2202
1-palmitoyl-2-linoleoyl-GPE (16:0/18:2)
>0.1
[−0.6725, 0.1]
<−0.6725
Asparagine
>0.076
[−0.0313, 0.076]
<−0.0313
1-palmitoyl-2-oleoyl-GPE (16:0/18:1)
>−0.032
[−0.8361, −0.032]
<−0.8361
1-arachidoyl-GPC (20:0)
>0.097
[−0.0527, 0.097]
<−0.0527
phosphatidylcholine (18:0/20:2, 20:0/18:2)
>0.01
[−0.1297, 0.01]
<−0.1297
Taurodeoxycholate
>−0.568
[−1.5714, −0.568]
<−1.5714
Glycerol
<−0.139
[−0.139, 0.3271]
>0.3271
Cystine
<−0.099
[−0.099, 0.1832]
>0.1832
C-glycosyltryptophan
<−0.09
[−0.09, −0.004]
>−0.004
cysteine-glutathione disulfide
<−0.073
[−0.073, 0.1492]
>0.1492
N-acetylglucosaminylasparagine
<−0.293
[−0.293, −0.027]
>−0.027
N-lactoyl valine
<−0.184
[−0.184, −0.0656]
>−0.0656
5-(galactosylhydroxy)-lysine
<−0.05
[−0.05, −0.0732]
>−0.0732
3-hydroxymyristate
<−0.123
[−0.123, 0.135]
>0.135
Hydroxyasparagine
<−0.021
[−0.021, 0.0491]
>0.0491
Guanidinosuccinate
<−0.155
[−0.155, 0.1489]
>0.1489
N-lactoyl tyrosine
<−0.237
[−0.237, −0.1281]
>−0.1281
1-methylhistidine
<−0.048
[−0.048, 0.0389]
>0.0389
Glucuronate
<−0.109
[−0.109, 0.1462]
>0.1462
Ribonate
<−0.051
[−0.051, 0.1058]
>0.1058
1-methylguanidine
<−0.181
[−0.181, −0.202]
>−0.202
N,N-dimethylalanine
<−0.489
[−0.489, −0.1014]
>−0.1014
11-dehydrocorticosterone
<−0.26
[−0.26, 0.21]
>0.21
Cortisol
<−0.306
[−0.306, 0.3537]
>0.3537
2R,3R-dihydroxybutyrate
<−0.029
[−0.029, 0.2423]
>0.2423
mannitol/sorbitol
<−0.027
[−0.027, 0.6064]
>0.6064
n-propanol glucuronide
<−0.418
[−0.418, 0.7998]
>0.7998

### Claim 4 (depends on 1)

The method of claim 1, further comprising measuring at least two metabolites and diagnosing based on the comparison of each metabolite, wherein if each of the metabolites correspond to a different diagnosis, measuring an additional metabolite until a majority diagnosis is achieved.

### Claim 5 (depends on 1)

The method of claim 1, further comprising measuring at least three metabolites and diagnosing based on the comparison of each metabolite, wherein if each of the metabolites correspond to a different diagnosis, measuring an additional metabolite until a majority diagnosis is achieved.

### Claim 6 (depends on 1)

The method of claim 1, further comprising measuring at least four metabolites and diagnosing based on the comparison of each metabolite, wherein if each of the metabolites correspond to a different diagnosis or a majority diagnosis is not achieved, measuring an additional metabolite until a majority diagnosis is achieved.

### Claim 7 (depends on 1)

The method of claim 1, further comprising measuring at least five metabolites and diagnosing based on the comparison of each metabolite, wherein if each of the metabolites correspond to a different diagnosis or a majority diagnosis is not achieved, measuring an additional metabolite until a majority diagnosis is achieved.

### Claim 8 (depends on 1)

A method of enabling treatment or slowing progression of CM in a feline, comprising diagnosing preclinical CM or clinical CM in the feline according to claim 1 and recommending a composition for the feline, wherein the composition treats or slows the progression of preclinical or clinical CM in the feline.

### Claim 9 (depends on 8)

The method of claim 8, wherein the composition has a characteristic selected from the group consisting of (i) ratio of potassium to sodium from about 4:1 to about 1:1, (ii) magnesium in an amount from about 0.08 wt % to about 0.25 wt %, (iii) protein in an amount of at least 20 wt %, and (iv) combinations thereof.

### Claim 10 (depends on 8)

The method of claim 8, wherein the composition comprises medium chain triglycerides.

### Claim 11 (depends on 8)

The method of claim 8, wherein the composition further comprises a component selected from the group consisting of an omega-3 fatty acid, Vitamin E, magnesium, glycine, a sulfur-containing amino acid, and mixtures thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the omega-3 fatty acid is selected from the group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and mixtures thereof.

### Claim 13 (depends on 11)

The method of claim 11, wherein the sulfur-containing amino acid is selected from the group consisting of methionine, cysteine, taurine, and mixtures thereof.

### Claim 14 (depends on 8)

The method of claim 8, wherein the composition is a complete and nutritionally balanced pet food.

### Claim 15 (depends on 8)

The method of claim 8, wherein the composition further comprises (i) carnitine, (ii) glycine and methionine, (iii) glutamine, (iv) an antioxidant such as vitamin E and vitamin C, or (v) mixtures thereof.
